Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00107237 · ClinicalTrials.gov registry record · Phase 1

AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
3
Study locations

NCT00107237 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 16 participants, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00107237, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
3
Study locations

Study Summary

RATIONALE: AEE788 and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving AEE788 together with everolimus may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of AEE788 when given together with everolimus and to see how well they work in treating patients with recurrent or relapsed glioblastoma multiforme.

Conditions Studied

Brain and Central Nervous System Tumors

Interventions

  • DRUG everolimus
  • DRUG AEE788

Study Locations (3)

California

  • Jonsson Comprehensive Cancer Center at UCLA - Los Angeles

North Carolina

  • Duke Univaersity Medical Center - Durham

Texas

  • MD Anderson Cancer Center/University of Texas - Houston

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2003-10
Est. Completion 2006-06
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00107237

The ClinicalTrials.gov registry entry for NCT00107237 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (91% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which everolimus is the first listed.

NCT00107237 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, North Carolina, Texas.

Frequently Asked Questions

What is clinical trial NCT00107237 about?

NCT00107237 is a clinical study titled "AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme". RATIONALE: AEE788 and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving AEE788 together with everolimus may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best ...

What is the current status of trial NCT00107237?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2003-10. Estimated completion is 2006-06.

What conditions does trial NCT00107237 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.

What interventions are being tested in trial NCT00107237?

The interventions under investigation include: everolimus (DRUG), AEE788 (DRUG).

Who is sponsoring clinical trial NCT00107237?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00107237 being conducted?

This trial has 3 study locations across California, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Brain and Central Nervous System Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Brain and Central Nervous System Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.